RxDoctor Payments Data

Katherine Hsiao, MD

Urogynecology and Reconstructive Pelvic Surgery · San Francisco, CANPI 1437237674

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,000 of the $10,920 with a category attached, or 73.3%. Intuitive Surgical accounts for 73.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $8,042 and has fallen 96.5% since, to $284 in 2025.

$10,920in general payments, 2019–2025

Across 60 payments — averaging $182.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Hologic Sales And Service, LLC$2K
  • AbbVie$311
  • Acessa Health Inc.$266
  • Johnson & Johnson$131
  • Coopersurgical, Inc.$124
  • plus $384 from 9 others

What the payments were for

  • Speaking & faculty fees$8,00073%
  • Travel & lodging$5355%
  • Food & beverage$2,38522%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,920 in reported general payments places this provider in the 75th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.

See all urogynecology and reconstructive pelvic surgery providers in California

Medicare billing

Part B allowed, 2024
$23,129
Medicare patients
65
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImvexxyEstradiol11$4,246
Estradiol54$3,099
DottiEstradiol18$2,790
Estradiol (Twice Weekly)Estradiol21$2,558
ProgesteroneProgesterone, Micronized35$1,104
Raloxifene Hcl16$429

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →